The present disclosure generally relates to devices and methods for removing acute blockages from blood vessels during intravascular medical treatments. More specifically, the present disclosure relates to an actuated clot retrieval catheter.
Clot retrieval catheters and devices are used in mechanical thrombectomy for endovascular intervention, often in cases where patients are suffering from conditions such as acute ischemic stroke (AIS), myocardial infarction (MI), and pulmonary embolism (PE). Accessing remote areas such as the neurovascular bed is challenging with conventional technology, as the target vessels are small in diameter, distant relative to the site of insertion, and are highly tortuous.
The clot itself can complicate procedures by taking on a number of complex morphologies and consistencies, ranging from simple tube-shaped structures which assume the shape of the vessel to long, strand-like arrangements that can span multiple vessels at one time. The age of a clot can also affect its compliance, with older clots tending to be less compressible than fresh clots. Fibrin rich clots also present a challenge in having a sticky nature that can cause a clot to roll along the outer surface of a mechanical thrombectomy device rather than being gripped effectively. Combinations of soft and firm clot regions can also separate during aspiration, with fragmentation leading to distal embolization which can occur in vessels that cannot be reached with currently available devices. Additionally, breaking the bonds adhering the clot to the vessel wall without damaging fragile vessels is a significant challenge.
Conventional clot retrieval catheters, especially those for operating in the neurovascular blood vessels, can suffer from a number of drawbacks. First, the diameters of the catheters themselves must be small enough to be advanced into the vasculature, which is very small in the context of the neurovascular system. The catheter must also be sufficiently flexible to navigate the vasculature and endure high strains, while also having the axial stiffness to offer smooth advancement along the route. Once at the target site, typical objects to be retrieved from the body can be substantially larger in size than the catheter tip, making it more difficult to retrieve objects into the tip. For example, fibrin-rich clots can often be difficult to extract as they can become lodged in the tip of traditional fixed-mouth catheters. This lodging can cause softer portions of the clot to shear away from the firmer regions, leading to distal embolization.
Small diameters and fixed tip sizes can also be less efficient at directing the aspiration necessary to remove blood and thrombus material during the procedure. The aspiration suction must be strong enough such that any fragmentation occurring through the use of a mechanical thrombectomy device or other methods can, at the very least, be held stationary so that fragments cannot migrate and occlude distal vessels. When aspirating with a traditional fixed-mouth catheter, however, a significant portion of the aspiration flow ends up coming from vessel fluid proximal to the tip of the catheter where there is no clot. This significantly reduces aspiration efficiency, lowering the success rate of clot removal.
The disclosed design is aimed at providing an improved aspirating retrieval catheter which addresses the above-stated deficiencies.
Examples presented herein include devices and methods for removing acute blockages from blood vessels during intravascular medical treatments. More specifically, the present disclosure relates to an actuated clot retrieval catheter system. An example system for retrieving an obstruction in a blood vessel can include a catheter, a first conductive wire, and an electronic circuit. The electronic circuit can provide a first current to the first conductive wire. A frame can be located near the distal end of the catheter and can be in electrical communication with the first conductive wire. The frame can include a shape memory material that enables the frame, or a portion thereof, to transition from a martensite phase to an austenite phase when heated to above the material's austenite finish temperature. At least a first portion of the frame can be expandable from a collapsed configuration to an expanded configuration upon being heated by the first current.
The shape memory material can have a transition temperature above approximately 37° C. In some examples, the shape memory material can have a transition temperature of from approximately 45° C. to 55° C.
The system can include a thermoelectric cooling circuit in electrical communication with the frame. The at least a first portion of the frame can be collapsible from the expanded configuration to the collapsed configuration upon removal of heat by the thermoelectric cooling circuit.
At least a second portion of the frame can be collapsible from an open configuration to a collapsed configuration upon being heated.
The system can include a second conductive wire in electrical communication with the second portion of the frame. The second conductive wire can receive a second current from the electronic circuit.
The system can include a membrane cover disposed around the frame.
The frame can be located within an inner lumen of the catheter. In other examples, the frame extends from the distal end, for example like a funnel, to capture the occlusion.
The system can include a thermocouple in electrical communication with the frame. The thermocouple can help to remove heat from at least a portion of the frame.
The shape memory material can be in a martensite phase when the at least a first portion of the frame is in the collapsed configuration. The shape memory material can be in an austenite phase when the at least a first portion of the frame is in the expanded configuration.
An example method of retrieving an occlusive thrombus from a blood vessel of a patient can include delivering a catheter comprising a frame to a target site. The frame can include a shape memory material. The method can include delivering a first current to the frame. The current running through the frame can heat the frame to cause at least a first portion of the frame to change from a collapsed configuration to an expanded configuration. The method can include aspirating the occlusive thrombus into the frame. The catheter can be withdrawn with the occlusive thrombus from the patient.
The shape memory material of the frame can have a transition temperature of from approximately 45° C. to 55° C.
The method can include deactivating the first current. By deactivating the first current, the at least a first portion of the frame can cool to cause the at least a first portion of the frame to collapse upon the occlusive thrombus.
The method can include cooling the at least a first portion of the frame with a thermoelectric cooling circuit to cause the at least a first portion of the frame to collapse upon the occlusive thrombus. The thermoelectric cooling circuit can include a Peltier chip, a thermoelectric wire, and the like.
The method can include delivering a second current to at least a second portion of the frame. The second current can create heat, through the resistance of the shape memory material, that causes the at least a second portion of the frame to change from an expanded configuration to a collapsed configuration and upon the occlusive thrombus.
The method can include monitoring a temperature of the frame with a thermocouple in communication with the frame. The method can include deactivating the first current when the temperature is above a first temperature. This can ensure the vessel is not damaged by excessive heat.
The frame can be located within an inner lumen of the catheter. In these examples, causing the at least a first portion of the frame to expand from a collapsed configuration to an expanded configuration can cause an inner diameter of the of the catheter to increase.
An example method of manufacturing an actuated clot retrieval system can include heat setting a first shape memory material into a first frame having an expanded configuration. The method can include allowing the first shape memory material to cool and the first frame to collapse into a collapsed configuration. The method can include connecting the first frame to a first end of a first conductive wire disposed within a catheter wall of a catheter. The method can include connecting a second end of the first conductive wire to an electronic circuit. The method can include applying a membrane to the first frame and to a distal end of the catheter.
The method can include heat setting a second shape memory material into a second frame having a collapsed configuration. The method can include connecting the second frame to a first end of a second conductive wire disposed within the catheter wall. The method can include connecting a second end of the second conductive wire to the electronic circuit. The method can include applying the membrane to the second frame.
The first shape memory material and the second shape memory material can different alloys, and the first frame and the second frame can be coaxial and connected to the distal end of the catheter. In other words, the second frame can be circumferentially positioned upon the second frame such that the second frame can close upon the first frame.
The first shape memory material and the second shape memory material can include the same alloy, and the first shape memory material and the second shape memory material can have different austenite finish temperatures.
The method can include providing a first catheter layer and disposing the first conductive wire on the first catheter layer. The method can include applying a second catheter layer over the first conductive wire and a first anchor strut of the first frame. Connecting the first frame to the first end of the first conductive wire can include connecting the first anchor strut to the first conductive wire prior to applying the second catheter layer.
The method can include encasing the first frame with a ring to hold the first frame in the collapsed configuration. Applying the membrane to the first frame can include dipping the first frame and the ring into a membrane material and allowing the membrane material to cool.
The above and further aspects of this disclosure are further discussed with the following description of the accompanying drawings, in which like numerals indicate like structural elements and features in various figures. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating principles of the disclosure. The figures depict one or more implementations of the inventive devices, by way of example only, not by way of limitation. It is expected that those of skill in the art can conceive of and combining elements from multiple figures to better suit the needs of the user.
The herein disclosed solution is directed to a clot retrieval catheter capable of providing local flow restriction/arrest via a modular distal frame. Flow restriction and large tipped designs offer substantially greater aspiration efficiency. Such advantages can also be especially beneficial in the case of stroke intervention procedures, where vessels in the neurovascular bed are particularly small and circuitous, and as a result a tailored axial and bending stiffness profile can inhibit kinking and binding. The catheter can also be compatible with relatively low-profile access sheaths and outer catheters, so that a puncture wound in the patient's groin (in the case of femoral access) can be easily and reliably closed. The catheter can also feature internal and/or external low-friction liners, and an outer polymer jacket or membrane disposed around the support structure. The membrane can be an elastomeric material that encapsulates the frame or is fitted over the frame so that the frame can move independently of the membrane. The membrane can be tight or loose fitting. A loose-fitting elastomeric membrane will be easier to open that a tight fitting membrane. The membrane can be baggy and made of a non-elastomeric material such that the force to open the membrane is low compared to that of a tight-fitting elastomeric membrane. The membrane can be inverted to extend distally from a proximal location radially inwardly of the frame before reverting back to extend proximally radially outwardly of the frame and wherein the inner and outer layers of the membrane are bonded or reflowed together at a proximal location or for the full length of the membrane. The membrane can comprise an inner and an outer tube, the proximal and distal ends of the inner and outer tube being bonded together or reflowed such that the two tubes form a sock around the frame, the frame being free to move/expand within the sock.
These improvements can lead to safe and more rapid access of a catheter and other devices to complex areas in order to remove occlusions and shorten procedure times. While the description is in many cases in the context of mechanical thrombectomy treatments, the systems and methods can be adapted for other procedures and in other body passageways as well.
Accessing the various vessels within the vascular system, whether they are coronary, pulmonary, or cerebral, involves well-known procedural steps and the use of a number of conventional, commercially-available accessory products. These products, such as angiographic materials, rotating hemostasis valves, and guidewires are widely used in laboratory and medical procedures. When these products are employed in conjunction with the system and methods in the description below, their function and exact constitution are not known in the related art.
The present systems and methods employ the characteristics of shape memory materials to customize the distal dimensions of a clot-retrieval device. Shape memory materials are those materials, such as alloys, that can be deformed when cold and then expand to a predetermined shape when heated. Once the heat is removed from the material, the material can return to it's collapsed, pliable shape. This can be achieved by heating the shape memory material beyond an austenite finish (AF) temperature. Below the AF temperature, the shape material exits its martensite phase, which is characterized by high elasticity, pliability, and flexibility. Above the AF temperature, the shape material exists in its austenite phase, which is characterized by a more rigid state. The shape memory material can be heat set to a predetermined shape above its AF temperature such that, when the material is reheated to the AF temperature, the material returns to that predetermined shape.
Various embodiments described herein can include frames that can resemble a funnel sheath that, once expanded, can exert a radial force on the vasculature. Fluid can be aspirated into the expanded funnel and then into a catheter to capture a thrombus within the funnel. The frame can include a membrane covering that directs the aspirate into the catheter. In other examples, the frame can be disposed within an inner lumen of the catheter. As the frame expands and collapses, the inner diameter of the catheter can be increased and decreased to adjust the flow rate into the catheter.
The present disclosure provides a mechanism for heating the frame to its AF temperature to cause the frame to transition into its austenite phase. One or more conductive lead wires can provide a current to the frame. The natural electrical resistance of the shape memory material can then cause the frame to heat above the AF temperature. A thermocouple can also be provided to monitor the temperature of the frame such that the frame does not overheat and cause trauma to the surrounding vasculature. In some examples, a thermoelectric cooling circuit, such as a Peltier chip, can be provided to transition the frame back into its martensite phase. The present disclosure provides various example designs for frames.
Various devices and methods are disclosed for providing an actuated clot retrieval catheter, and examples of the devices and methods will now be described with reference to the accompanying figures.
The frame 110 can be encapsulated within an inverted membrane, dual layer sealed membrane or an overmoulded or dipped membrane. Where the frame 110 is housed within an inner and outer membrane layer, the frame can have unhindered movement. Where an overmoulded membrane is supplied, there may be more resistance as the frame 110 may be required to stretch more discrete areas of membrane material. It is appreciated that, as an electrical current will be passed through the frame 110, it can be insulated in order to contain the electrical current. The membrane material can serve to insulate the frame 110. The frame 110, acting as a resistor, can thereby generate heat under a current load.
The frame 110 can have an expanded configuration and a collapsed configuration.
Shape memory materials enable devices to be manufactured such that, once heated above an AF temperature, the device can be pre-set into a predetermined shape. Considering the example funnel-shaped frame 110 of
Referring again to
As used herein, the terms “about” or “approximately” for any numerical values or ranges indicate a suitable dimensional tolerance that allows the part or collection of components to function for its intended purpose. More specifically, “about” or “approximately” may refer to the range of values ±10% of the recited value, e.g. “about 50° C.” may refer to the range of values from 45.001° C. to 54.999° C.
The frame 110 can be heated by providing a current to the frame 110. The high electrical resistance of the shape memory material, for example Nitinol, can cause the frame 110 to heat in response to the electrical current and the heat in turn cause the transition from the martensite to austenite phase. The system 100 can include an electronic circuit 112 to provide the required current to the frame 110. The electronic circuit 112 can be disposed within a circuit housing 106. The electronic circuit 112 can be activated with a switch 114. The electronic circuit 112 can feed from approximately 300 mA to approximately 1500 mA (e.g., approximately 500 mA to approximately 1000 mA) to the frame 110 using a power supply ranging, for example, from approximately 3 to 12V, more preferably from approximately 5 to 9V. The current can be pulsed from 1 to 1000 msec, more preferable from 100 to 500 msec with a break in current of between 1 and 1000 msec, more preferably from 1 to 100 msec. Pulsing allows the temperature of the frame to be maintained between a set temperature range, the on segment of the pulses heating and the off segment of the pulse allowing the frame to cool such that the temperature is kept between a range. The temperature can be monitored by a thermocouple such that the pulses can be altered if the temperature goes out of range; for example, a continuous feed of current can be used to ramp up the temperature quickly and the pulses can be lowered keep the temperature of the frame under the upper range.
One or more conductive wires 116 (e.g., a positive lead 118 and a negative lead 120) can extend between the electronic circuit 112 and the frame 110 to provide the electrical current to heat the frame 110. Cutout A of
The system 100 can include a thermocouple 122 connected to the frame 110 to monitor the temperature of the frame 110. If the frame 110 is heated above a certain temperature, the frame 110 can burn the surrounding vasculature. To this end, the thermocouple 122 can monitor the temperature of the frame 110 as it is heated by the current. If the frame 110 exceeds a certain temperature, for example 50° C., the thermocouple 122 can communicate this information to the electronic circuit 112 to deactivate the current being supplied to the frame 110. The thermocouple 122 can comprise a platinum or stainless steel wire that can be welded between the frame 110 (e.g., at an anchor strut 206) and a conductive wire 116, where the electronic circuit 112 measures the difference in resistivity between the shape memory material and the thermocouple wire to determine the temperature of the frame 110. This can be calibrated and can have a linear temperature relationship.
The system 100 can include a thermoelectric cooling circuit 123 in electrical communication with the frame 110. The thermoelectric cooling circuit 123 can include, for example, a Peltier chip, disposed proximate the frame 110. As described above, when the frame 110 is cooled below the AF temperature, the shape memory material of the frame can transition back into the pliable, flexible martensite phase. This can be completed to capture the clot 40 in the frame 110. Instead of allowing the shape memory material to cool naturally, the thermoelectric cooling circuit 123 can pump heat from the frame 110 to cool the frame 110 more rapidly.
The frame 110 can be characterized by a plurality of struts 124 that can form closed cells 126, loops, or undulating patterns. A plurality of distal hoops or crown struts (which will be described below) can form the circumferential perimeter of the frame opening 128. The frame 110 can have a variety of shapes, including a low profile rounded tip, an open mouth funnel as shown, or other shapes that will be described herein. The plurality of struts 124 can be enclosed within a membrane 130. The membrane 130 can provide a means to direct fluid aspirate into the frame 110 and into the catheter 102. The membrane 130 can also maintain the position of the struts 124 when the frame 110 is in a collapsed configuration. Suitable membrane 130 materials can include elastic polyurethanes such as Chronoprene, Chronosil, Chronoflex, and other silicon and urethane polymers and the like that have high elasticity and insulative properties with good tear resistance. The membrane 130 can have a low hardness to enable the membrane 130 to stretch when the frame 110 is expanded. For example, the membrane 130 can have a Shore hardness typical of 00 ranges and Shore A0.1 to Shore A100 (e.g., Shore A40 to Shore A80). Because the membrane 130 is encapsulating the frame 110, which may be intended to expand, the membrane 130 can also have a degree of expandability, for example from 200-2200% (e.g., 400-800%).
The struts 124 can be coated with a film of material with high dielectric strength such as Parylene to insulate the struts from blood, which is a conductor, for example if the frame 110 is not fully encapsulated or sealed by the membrane 130.
Referring again to
In some examples, the frame 110 does not include longitudinal struts 204, but instead the multiple annular crowns 202 can connected at each peak such that the cells 126 form a diamond-shaped lattice structure. Uniform spacing of the diamond-shaped cells 126 can also promote even expansion of the frame 110 and membrane 130. In yet other examples, the frame 110 does not include longitudinal struts 204, and the multiple annular crowns 202 are not connected at peaks. In these examples, the annular crowns 202 can instead be held into place by the membrane 130.
The shapes and configurations of the frame 110 described herein can be created by laser cutting the design into a tube. After laser cutting the design, the frame 110 can be positioned into its desired configuration and heat set such that the frame 110 can return to that desired configuration when heated during a procedure.
The frame 110 can include one or more anchor struts 206 extending proximally. The conductive wire 116 can be connected to the one or more anchor struts 206 to provide the current to the frame 110. As shown in
The frame 110 can be kept short with minimal travel path (length of strut 124 and cross section, long length and large cross section will have greatest resistance) for current such that resistance is kept to a minimum so that the basket of the frame 110 can heat up and expand rapidly.
Certain junctions between struts 124 can be connected with an insulating junction 304 such the current does not pass from one side of the insulating junction 304 to the other. This enables heat to be applied to the frame in a controlled pattern. Controlling the heat applied to different areas of the frame 110 enables certain portions of the frame to transition into an austenite phase while other portions do not transition. In some examples, as described above, insulating certain portions of the frame 110 also enables the frame 110 to have a distinct activation sequence. A first portion of the frame 110 can be configured to expand upon receiving current and a second portion of the frame can be configured to collapse upon receiving current. This can enable the user to collapse the frame 110 by applying a current to one portion of the frame 110 instead of waiting for the shape memory material to cool. Current can flow through a negative lead 120 into one side of a frame 110 and flow in an even electrical resistance path to the other side of the frame 110 where it returns through a positive lead 118. For example, if an anchor strut 206 of the frame 110 is connected to a v-shaped expansion strut of the frame 110, the anchor strut 206 can be approximately twice the cross-sectional area of each of the struts 124 that form the v-shaped expansion strut. This will allow for even flow of resistance between struts. Segments of the expansion frame can be divided by insulators and different segments can each have independent sets of positive and negative lead wires.
In some examples, two of the anchor struts (e.g., anchor struts 206A and 206C) can connect to a positive lead 118 and a negative lead 120 for a first portion of the frame 110 (e.g., first portion 111A); and two of the anchor struts (e.g., anchor struts 206B and 206D) can connect to a positive lead 118 and a negative lead 120 for a second portion of the frame 110 (e.g., second portion 111B). This can enable the first portion 111A of the frame 110 to have a different activation characteristic than the second portion 111B of the frame 110. The first portion 111A of the frame 110 can be heat-set into an expanded configuration. By providing a current, and thus creating heat through resistance, the first portion 111A can expand during the procedure. The second portion 111B of the frame 110 can be heat-set into a collapsed configuration. By providing a current, and thus creating heat through resistance, the second portion 111B can collapse during the procedure. This enables a user of the system to advance the system 100 to the target site 20, direct a first current to the first portion 111A to expand frame 110, and aspirate the clot 40 into the frame 110. The user can then direct a second current to the second portion 111B to collapse the frame 110 and capture the clot 40. As is described above, the individual anchor struts 206A,206B,206C,206D can have electrical connections 401 to different components of the system 100. For examples with a first portion 111A and a second portion 111B, this means that two of the electrical connections 401 can include a second positive lead wire and a second negative lead wire, respectively, to heat one of the frame portions independently of the other, each circuit being insulated from the other.
The first portion 111A and second portion 111B of the frame 110 can comprise the same shape memory material and each material can have the same AF temperature. In other examples, the two portions can comprise the same material but have different AF temperatures. The first portion 111A and second portion 111B can comprise different shape memory materials, which can also enable the portions to have different AF temperatures, if needed. In examples having two portions with different AF temperatures, one portion can have an AF temperature below that of human blood (e.g., below 37° C.) such that it expands once delivered to the target site 20 and contacts blood; the other portion can have an AF temperature above 37° C. such that it only collapses upon being heated by a current. Conversely, one portion can have an AF temperature below that of human blood such that it collapses as it is heated by blood.
The first portion 111A and second portion 111B can be interconnected to form the cells 126 of the frame. When the first portion 111A and the second portion 111B of the frame 110 are intended to have different activation characteristics, heat from one portion can be shielded from the other portion by using an insulating junction 304 like the one shown in
As shown in
In an alternative embodiment, the distal end 108 of the catheter 102 itself can instead be actuated by a springing mechanism. For example, the catheter 102 can include a flexible portion that includes a shape memory material disposed therein. As the shape memory material in the catheter 102 expands with heat, the distal end 108 of the catheter 102 can extend through the funnel formed by the frame 110 and towards the clot.
In some examples, instead of extending from the catheter 102, the frame 110 can be positioned within an inner lumen 302 of the catheter 102. In a similar manner, as the frame 110 expands inside the inner lumen 302, the bore size of the catheter 102 can increase to adjust the flow.
In step 1910, method 1900 can include delivering a first current to the frame. The first current can be delivered through a conductive wire connecting the frame to an electronic circuit. The user can activate the electronic circuit outside of the patient.
In step 1915, method 1900 can include heating the frame to cause at least a first portion of the frame to change from a collapsed configuration to an expanded configuration. The heating of the frame is caused by the electrical resistance of the shape memory material as the current runs through the frame. At least a first portion of the frame means the entire frame can expand, though it is not necessary that the entire frame expands. As described above, the frame can have multiple portions with different transformation characteristics. For example, a first portion of the frame can be heated to expand while a second portion is not heated. The second portion, for example, can be heated in a later step to capture the thrombus. A shape memory funnel frame can be restricted from expanding by an electrically actuated member, removing the electric current allows the restraining member to release and the shape memory material expands from the heat of blood.
At step 1920, method 1900 can include aspirating the occlusive thrombus into the frame. The aspiration can be directed into the catheter by the frame, which can include a membrane covering that directs fluid.
At step 1920, method 1900 can include withdrawing the catheter with the occlusive thrombus from the patient. With the thrombus captured within the frame, the thrombus can be pulled from the vessel of the patient without worry of the thrombus dislodging from the catheter due to poor capture.
Method 1900 can end after step 1925. In other embodiments, additional steps according to the examples described above can be performed. For example, method 1900 can include deactivating the first current to cool the at least a first portion of the frame. Cooling the shape memory material can cause the at least a first portion to collapse upon the occlusive thrombus to improve the capture the thrombus for removal.
In some examples, method 1900 can include delivering a second current to at least a second portion of the frame. The second portion can have a different transformation characteristic than the first portion. For example, the second portion can be pre-set into a collapsed configuration in its austenite phase, which means that, once heated, it can collapse upon the thrombus. Accordingly, method 1900 can include heating, via the second current, the second portion of the frame to cause the second portion of the frame to change from an expanded configuration to a collapsed configuration and upon the occlusive thrombus.
Method 1900 can also include cooling the at least a first portion of the frame with a thermoelectric cooling circuit to cause the at least a first portion of the frame to collapse upon the occlusive thrombus. A thermoelectric cooling circuit, such as a Peltier chip, can pump heat from a system. Using this effect, the thermoelectric cooling circuit can cause the at least a first portion of the frame to cool and collapse more rapidly around the occlusive thrombus.
Method 1900 can include delivering the current in a series of pulses so as to maintain a steady frame temperature, and the electronic circuit can monitor the temperature and adjust the pulse duration and/or length accordingly.
Method 1900 can also include monitoring a temperature of the frame with a thermocouple. In some examples, the thermocouple can monitor to determine if the frame exceeds a certain temperature, for example 50° C., and deactivate the first current if the frame exceeds the temperature.
In step 2010, method 2000 can include allowing the first shape memory material to cool and the frame to collapse into a collapsed configuration. Once cooled, the frame is more flexible and pliable, as it is in its martensite phase. The collapsed frame can return to its predetermined shape by reheating the frame to above the AF temperature.
In step 2015, method 2000 can include connecting the first frame to a first end of a first conductive wire disposed within a wall of a catheter (e.g. catheter wall 306 of
In step 2020, method 2000 can include connecting a second end of the first conductive wire to an electronic circuit. The electronic circuit can be positioned distal to the frame. The electronic circuit can be disposed within a housing that includes a switch to activate the current.
In step 2025, method 2000 can include applying a membrane to the first frame and to a distal end of the catheter. The membrane can be applied by a variety of methods. One method is to apply a thin base layer of material to a dipping mandrel with the catheter in place, followed by injection molding an intermediate layer with collapsed frame held in place by an outer mold, and a final top layer can be applied using a second outer mold or through a final dip coating process. In some examples, a preformed ring of a material that will not form a bond with the encapsulation membrane can be used to hold the frame in a collapsed position. After sufficient material has encapsulated the frame through a dipping or molding process, the preformed ring can be removed before a final dipping or molding process to fill in the void left by the ring. Alternatively, a preformed ring of the same material can be used to avoid the necessity to remove the ring.
Method 2000 can end after step 2025. In other embodiments, additional steps according to the examples described above can be performed. For example, method 2000 can include heat setting a second shape memory material into a second frame having a collapsed configuration. The second frame can be heat set in a similar manner as described above for the first frame. The second frame can be heat set into a collapsed configuration such that, once heated, the second frame can return to the collapsed configuration (e.g., to capture a clot). Method 2000 can include allowing the second shape memory material to cool and then connecting the second frame to a first end of a second conductive wire disposed within the catheter wall. Method 2000 can include connecting a second end of the second conductive wire to the electronic circuit so that the second frame can receive a current. The membrane can be applied to the second frame in a similar manner to the method described for the first frame. The first shape memory material and the second shape memory material can be the same alloys or can be different alloys. Providing different alloys can enable the two frames to have different transformation characteristics (e.g., they can transform from martensite to austenite phases at different temperatures). The first frame and the second frame can be coaxial and connected to the distal end of the catheter. In this manner, the first frame can expand when heated, and the second frame can collapse upon the first frame to capture the clot when heated.
The descriptions contained herein are examples of embodiments of the disclosure and are not intended in any way to limit the scope of the disclosure. As described herein, the disclosure contemplates many variations and modifications of the aspiration device including using alternative geometries of structural elements, combining shapes and structural elements from various example embodiments, using alternative materials, etc. These modifications would be apparent to those having ordinary skill in the art to which this disclosure relates and are intended to be within the scope of the claims which follow.
This application claims priority, and benefit under 35 U.S.C. § 119(e), to U.S. Provisional Patent Application No. 62/813,723, filed 4 Mar. 2019, which is incorporated herein by reference as if fully set forth below.
Number | Name | Date | Kind |
---|---|---|---|
4243040 | Beecher | Jan 1981 | A |
4324262 | Hall | Apr 1982 | A |
4351342 | Wiita et al. | Sep 1982 | A |
4575371 | Nordqvist et al. | Mar 1986 | A |
4719924 | Crittenden et al. | Jan 1988 | A |
4738666 | Fuqua | Apr 1988 | A |
4767404 | Renton | Aug 1988 | A |
4793348 | Palmaz | Dec 1988 | A |
4873978 | Ginsburg | Oct 1989 | A |
5011488 | Ginsburg | Apr 1991 | A |
5092839 | Kipperman | Mar 1992 | A |
5102415 | Guenther et al. | Apr 1992 | A |
5122136 | Guglielmi et al. | Jun 1992 | A |
5123840 | Nates | Jun 1992 | A |
5171233 | Amplatz | Dec 1992 | A |
5234437 | Sepetka | Aug 1993 | A |
5256144 | Kraus et al. | Oct 1993 | A |
5372124 | Takayama | Dec 1994 | A |
5385562 | Adams | Jan 1995 | A |
5387219 | Rappe | Feb 1995 | A |
5387226 | Miraki | Feb 1995 | A |
5396902 | Brennen et al. | Mar 1995 | A |
5449372 | Schmaltz | Sep 1995 | A |
5520651 | Sutcu | May 1996 | A |
5538512 | Zenzon et al. | Jul 1996 | A |
5549626 | Miller et al. | Aug 1996 | A |
5558652 | Henke | Sep 1996 | A |
5609627 | Goicoechea et al. | Mar 1997 | A |
5624461 | Mariant | Apr 1997 | A |
5639277 | Mariant | Jun 1997 | A |
5645558 | Horton | Jul 1997 | A |
5658296 | Bates | Aug 1997 | A |
5662671 | Barbut | Sep 1997 | A |
5695519 | Summer et al. | Dec 1997 | A |
5709704 | Nott et al. | Jan 1998 | A |
5713853 | Clark | Feb 1998 | A |
5728078 | Powers, Jr. | Mar 1998 | A |
5769871 | Mers Kelly | Jun 1998 | A |
5779716 | Cano | Jul 1998 | A |
5810874 | Lefebvre | Sep 1998 | A |
5814064 | Danniel et al. | Sep 1998 | A |
5827304 | Hart | Oct 1998 | A |
5855598 | Pinchuk | Jan 1999 | A |
5893869 | Barnhart et al. | Apr 1999 | A |
5895398 | Wensel | Apr 1999 | A |
5897567 | Ressemann | Apr 1999 | A |
5904698 | Thomas et al. | May 1999 | A |
5911725 | Boury | Jun 1999 | A |
5935139 | Bates | Aug 1999 | A |
5938645 | Gordon | Aug 1999 | A |
5947995 | Samuels | Sep 1999 | A |
5968057 | Taheri | Oct 1999 | A |
5971938 | Hart et al. | Oct 1999 | A |
5997939 | Moechnig et al. | Dec 1999 | A |
6063113 | Kavteladze | May 2000 | A |
6066149 | Samson et al. | May 2000 | A |
6066158 | Engelson | May 2000 | A |
6093196 | Okada | Jul 2000 | A |
6093199 | Brown et al. | Jul 2000 | A |
6096053 | Bates | Aug 2000 | A |
6099534 | Bates | Aug 2000 | A |
6102932 | Kurz | Aug 2000 | A |
6106548 | Roubin et al. | Aug 2000 | A |
6129739 | Khosravi | Oct 2000 | A |
6146396 | Konya et al. | Nov 2000 | A |
6146404 | Kim | Nov 2000 | A |
6165194 | Denardo | Dec 2000 | A |
6165199 | Barbut | Dec 2000 | A |
6168604 | Cano | Jan 2001 | B1 |
6168622 | Mazzocchi | Jan 2001 | B1 |
6174318 | Bates et al. | Jan 2001 | B1 |
6179861 | Khosravi | Jan 2001 | B1 |
6203561 | Ramee | Mar 2001 | B1 |
6214026 | Lepak | Apr 2001 | B1 |
6221006 | Dubrul | Apr 2001 | B1 |
6238412 | Dubrul | May 2001 | B1 |
6245087 | Addis | Jun 2001 | B1 |
6251122 | Tsukernik | Jun 2001 | B1 |
6254571 | Hart | Jul 2001 | B1 |
6264663 | Cano | Jul 2001 | B1 |
6306163 | Fitz | Oct 2001 | B1 |
6309379 | Willard | Oct 2001 | B1 |
6312444 | Barbut | Nov 2001 | B1 |
6315778 | Gambale et al. | Nov 2001 | B1 |
6325819 | Pavcnik et al. | Dec 2001 | B1 |
6334864 | Amplatz et al. | Jan 2002 | B1 |
6336934 | Gilson et al. | Jan 2002 | B1 |
6348056 | Bates | Feb 2002 | B1 |
6350271 | Kurz et al. | Feb 2002 | B1 |
6361545 | Macoviak | Mar 2002 | B1 |
6375668 | Gifford et al. | Apr 2002 | B1 |
6383205 | Samson et al. | May 2002 | B1 |
6383206 | Gillick | May 2002 | B1 |
6391037 | Greenhalgh | May 2002 | B1 |
6402771 | Palmer | Jun 2002 | B1 |
6409683 | Fonseca et al. | Jun 2002 | B1 |
6416541 | Denardo | Jul 2002 | B2 |
6425909 | Dieck et al. | Jul 2002 | B1 |
6432122 | Gilson et al. | Aug 2002 | B1 |
6436112 | Wensel | Aug 2002 | B2 |
6458139 | Palmer | Oct 2002 | B1 |
6346116 | Brooks et al. | Nov 2002 | B1 |
6485497 | Wensel | Nov 2002 | B2 |
6485501 | Green | Nov 2002 | B1 |
6485502 | Don Michael | Nov 2002 | B2 |
6511492 | Rosenbluth | Jan 2003 | B1 |
6517551 | Driskill | Feb 2003 | B1 |
6520934 | Lee et al. | Feb 2003 | B1 |
6520951 | Carrillo, Jr | Feb 2003 | B1 |
6530935 | Wensel | Mar 2003 | B2 |
6530939 | Hopkins | Mar 2003 | B1 |
6540768 | Diaz et al. | Apr 2003 | B1 |
6544279 | Hopkins | Apr 2003 | B1 |
6551341 | Boylan et al. | Apr 2003 | B2 |
6551342 | Shen et al. | Apr 2003 | B1 |
6575997 | Palmer et al. | Jun 2003 | B1 |
6582448 | Boyle | Jun 2003 | B1 |
6585756 | Strecker | Jul 2003 | B1 |
6589265 | Palmer et al. | Jul 2003 | B1 |
6592607 | Palmer et al. | Jul 2003 | B1 |
6592616 | Stack | Jul 2003 | B1 |
6602271 | Adams | Aug 2003 | B2 |
6602272 | Boylan et al. | Aug 2003 | B2 |
6605102 | Mazzocchi et al. | Aug 2003 | B1 |
6610077 | Hancock et al. | Aug 2003 | B1 |
6616679 | Khosravi | Sep 2003 | B1 |
6632241 | Hanoock et al. | Oct 2003 | B1 |
6638245 | Miller | Oct 2003 | B2 |
6638293 | Makower et al. | Oct 2003 | B1 |
6641590 | Palmer et al. | Nov 2003 | B1 |
6652555 | VanTassel et al. | Nov 2003 | B1 |
6656218 | Denardo et al. | Dec 2003 | B1 |
6660021 | Palmer et al. | Dec 2003 | B1 |
6663650 | Sepetka | Dec 2003 | B2 |
6673089 | Yassour et al. | Jan 2004 | B1 |
6685722 | Rosenbluth | Feb 2004 | B1 |
6692504 | Kurz et al. | Feb 2004 | B2 |
6692508 | Wensel | Feb 2004 | B2 |
6692509 | Wensel | Feb 2004 | B2 |
6702782 | Miller | Mar 2004 | B2 |
6712834 | Yassour et al. | Mar 2004 | B2 |
6726701 | Gilson et al. | Apr 2004 | B2 |
6730104 | Sepetka | May 2004 | B1 |
6726703 | Broome et al. | Aug 2004 | B2 |
6824545 | Sepetka | Nov 2004 | B2 |
6855155 | Denardo et al. | Feb 2005 | B2 |
6878163 | Denardo et al. | Apr 2005 | B2 |
6890340 | Duane | May 2005 | B2 |
6913612 | Palmer | Jul 2005 | B2 |
6913618 | Denardo et al. | Jul 2005 | B2 |
6953472 | Palmer et al. | Oct 2005 | B2 |
6989019 | Mazzocchi | Jan 2006 | B2 |
6989021 | Bosma et al. | Jan 2006 | B2 |
6994718 | Groothuis et al. | Feb 2006 | B2 |
6997939 | Linder | Feb 2006 | B2 |
7004954 | Voss et al. | Feb 2006 | B1 |
7004955 | Shen | Feb 2006 | B2 |
7004956 | Palmer | Feb 2006 | B2 |
7008434 | Kurz et al. | Mar 2006 | B2 |
7033376 | Tsukernik | Apr 2006 | B2 |
7041116 | Goto | May 2006 | B2 |
7048758 | Boyle | May 2006 | B2 |
7058456 | Pierce | Jun 2006 | B2 |
7063707 | Bose | Jun 2006 | B2 |
7153320 | Euteneuer et al. | Dec 2006 | B2 |
7175655 | Malaei | Feb 2007 | B1 |
7179273 | Palmer et al. | Feb 2007 | B1 |
7220269 | Ansel | May 2007 | B1 |
7220271 | Clubb | May 2007 | B2 |
7226464 | Garner et al. | Jun 2007 | B2 |
7229472 | DePalma et al. | Jun 2007 | B2 |
7232462 | Schaeffer | Jun 2007 | B2 |
7288112 | Denardo et al. | Oct 2007 | B2 |
7306618 | Demond | Dec 2007 | B2 |
7316692 | Huffmaster | Jan 2008 | B2 |
7323001 | Cubb | Jan 2008 | B2 |
7331976 | McGuckin, Jr. et al. | Feb 2008 | B2 |
7344550 | Carrison et al. | Mar 2008 | B2 |
7399308 | Borillo et al. | Jul 2008 | B2 |
7410491 | Hopkins | Aug 2008 | B2 |
7452496 | Brady et al. | Nov 2008 | B2 |
7491215 | Vale et al. | Feb 2009 | B2 |
7491216 | Brady | Feb 2009 | B2 |
7510565 | Gilson et al. | Mar 2009 | B2 |
7534252 | Sepetka | May 2009 | B2 |
7556636 | Mazzocchi | Jul 2009 | B2 |
7582111 | Krolik et al. | Sep 2009 | B2 |
7594926 | Linder | Sep 2009 | B2 |
7604649 | McGuckin et al. | Oct 2009 | B2 |
7618434 | Santra et al. | Nov 2009 | B2 |
7662165 | Gilson et al. | Feb 2010 | B2 |
7670356 | Mazzocchi | Mar 2010 | B2 |
7691121 | Rosenbluth | Apr 2010 | B2 |
7691124 | Balgobin | Apr 2010 | B2 |
7708770 | Linder | May 2010 | B2 |
7736385 | Agnew | Jun 2010 | B2 |
7766934 | Pal | Aug 2010 | B2 |
7771452 | Pal | Aug 2010 | B2 |
7780694 | Palmer | Aug 2010 | B2 |
7780696 | Daniel et al. | Aug 2010 | B2 |
7819893 | Brady et al. | Oct 2010 | B2 |
7828815 | Mazzocchi | Nov 2010 | B2 |
7846176 | Mazzocchi | Nov 2010 | B2 |
7846175 | Bonnette et al. | Dec 2010 | B2 |
7850708 | Pal | Dec 2010 | B2 |
7887560 | Kusleika | Feb 2011 | B2 |
7901426 | Gilson et al. | Mar 2011 | B2 |
7914549 | Morsi | Mar 2011 | B2 |
7922732 | Mazzocchi | Apr 2011 | B2 |
7927784 | Simpson | Apr 2011 | B2 |
7931659 | Bose et al. | Apr 2011 | B2 |
7998165 | Huffmaster | Aug 2011 | B2 |
8002822 | Glocker et al. | Aug 2011 | B2 |
8021379 | Thompson et al. | Sep 2011 | B2 |
8021380 | Thompson et al. | Sep 2011 | B2 |
8043326 | Hancock et al. | Oct 2011 | B2 |
8048151 | O'Brien et al. | Nov 2011 | B2 |
8052640 | Fiorella et al. | Nov 2011 | B2 |
8057497 | Raju et al. | Nov 2011 | B1 |
8066757 | Ferrera et al. | Nov 2011 | B2 |
8070791 | Ferrera et al. | Dec 2011 | B2 |
8088140 | Ferrera et al. | Jan 2012 | B2 |
8100935 | Rosenbluth et al. | Jan 2012 | B2 |
8109941 | Richardson | Feb 2012 | B2 |
8118829 | Carrison et al. | Feb 2012 | B2 |
8123769 | Osborne | Feb 2012 | B2 |
8137377 | Palmer et al. | Mar 2012 | B2 |
8142422 | Makower et al. | Mar 2012 | B2 |
8142442 | Palmer et al. | Mar 2012 | B2 |
8182508 | Magnuson et al. | May 2012 | B2 |
8187298 | Pal | May 2012 | B2 |
8246641 | Osborne et al. | Aug 2012 | B2 |
8246672 | Osborne | Aug 2012 | B2 |
8252017 | Paul, Jr. et al. | Aug 2012 | B2 |
8252018 | Valaie | Aug 2012 | B2 |
8357178 | Grandfield et al. | Jan 2013 | B2 |
8357179 | Grandfield et al. | Jan 2013 | B2 |
8357893 | Xu et al. | Jan 2013 | B2 |
8361095 | Osborne | Jan 2013 | B2 |
8366663 | Fiorella et al. | Feb 2013 | B2 |
8372133 | Douk et al. | Feb 2013 | B2 |
8409215 | Sepetka et al. | Apr 2013 | B2 |
8419748 | Valaie | Apr 2013 | B2 |
8460312 | Bose et al. | Jun 2013 | B2 |
8460313 | Huffmaster | Jun 2013 | B2 |
8486104 | Samson et al. | Jul 2013 | B2 |
8529596 | Grandfield et al. | Sep 2013 | B2 |
8574262 | Ferrera et al. | Nov 2013 | B2 |
8579915 | French et al. | Nov 2013 | B2 |
8585713 | Ferrera et al. | Nov 2013 | B2 |
8608761 | Osbourne et al. | Dec 2013 | B2 |
8679142 | Slee et al. | Mar 2014 | B2 |
8696622 | Fiorella et al. | Apr 2014 | B2 |
8702652 | Fiorella et al. | Apr 2014 | B2 |
8702724 | Olsen et al. | Apr 2014 | B2 |
8784434 | Rosenbluth et al. | Jul 2014 | B2 |
8784441 | Rosenbluth et al. | Jul 2014 | B2 |
8795305 | Grandfield et al. | Aug 2014 | B2 |
8795317 | Grandfield et al. | Aug 2014 | B2 |
8795345 | Grandfield et al. | Aug 2014 | B2 |
8814892 | Galdonik et al. | Aug 2014 | B2 |
8814925 | Hilaire et al. | Aug 2014 | B2 |
8900265 | Ulm, III | Dec 2014 | B1 |
8939991 | Krolick et al. | Jan 2015 | B2 |
8945143 | Ferrera et al. | Feb 2015 | B2 |
8945172 | Ferrera et al. | Feb 2015 | B2 |
8968330 | Rosenbluth et al. | Mar 2015 | B2 |
9039749 | Shrivastava et al. | May 2015 | B2 |
9072537 | Grandfield et al. | Jul 2015 | B2 |
9113936 | Palmer et al. | Aug 2015 | B2 |
9119656 | Bose et al. | Sep 2015 | B2 |
9138307 | Valaie | Sep 2015 | B2 |
9149609 | Ansel et al. | Oct 2015 | B2 |
9155552 | Ulm, III | Oct 2015 | B2 |
9161766 | Slee et al. | Oct 2015 | B2 |
9173668 | Ulm, III | Nov 2015 | B2 |
9186487 | Dubrul et al. | Nov 2015 | B2 |
9198687 | Fulkerson et al. | Dec 2015 | B2 |
9204887 | Cully et al. | Dec 2015 | B2 |
9221132 | Bowman | Dec 2015 | B2 |
9232992 | Heidner | Jan 2016 | B2 |
9532792 | Galdonik et al. | Jan 2017 | B2 |
9532873 | Kelley | Jan 2017 | B2 |
9533344 | Monetti et al. | Jan 2017 | B2 |
9539011 | Chen et al. | Jan 2017 | B2 |
9539022 | Bowman | Jan 2017 | B2 |
9539122 | Burke et al. | Jan 2017 | B2 |
9539382 | Nelson | Jan 2017 | B2 |
9549830 | Bruszewski et al. | Jan 2017 | B2 |
9554805 | Tompkins et al. | Jan 2017 | B2 |
9561125 | Bowman et al. | Feb 2017 | B2 |
9572982 | Burnes et al. | Feb 2017 | B2 |
9579484 | Barnell | Feb 2017 | B2 |
9585642 | Dinsmoor et al. | Mar 2017 | B2 |
9615832 | Bose et al. | Apr 2017 | B2 |
9615951 | Bennett et al. | Apr 2017 | B2 |
9622753 | Cox | Apr 2017 | B2 |
9636115 | Henry et al. | May 2017 | B2 |
9636439 | Chu et al. | May 2017 | B2 |
9642635 | Vale et al. | May 2017 | B2 |
9642675 | Werneth et al. | May 2017 | B2 |
9655633 | Leynov et al. | May 2017 | B2 |
9655645 | Staunton | May 2017 | B2 |
9655989 | Cruise et al. | May 2017 | B2 |
9662129 | Galdonik et al. | May 2017 | B2 |
9662238 | Dwork et al. | May 2017 | B2 |
9662425 | Lilja et al. | May 2017 | B2 |
9668898 | Wong | Jun 2017 | B2 |
9675477 | Thompson | Jun 2017 | B2 |
9675782 | Connolly | Jun 2017 | B2 |
9676022 | Ensign et al. | Jun 2017 | B2 |
9692557 | Murphy | Jun 2017 | B2 |
9693852 | Lam et al. | Jul 2017 | B2 |
9700262 | Janik et al. | Jul 2017 | B2 |
9700399 | Acosta-Acevedo | Jul 2017 | B2 |
9717421 | Griswold et al. | Aug 2017 | B2 |
9717500 | Tieu et al. | Aug 2017 | B2 |
9717502 | Teoh et al. | Aug 2017 | B2 |
9724103 | Cruise et al. | Aug 2017 | B2 |
9724526 | Strother et al. | Aug 2017 | B2 |
9750565 | Bloom et al. | Sep 2017 | B2 |
9757260 | Greenan | Sep 2017 | B2 |
9764111 | Gulachenski | Sep 2017 | B2 |
9770251 | Bowman et al. | Sep 2017 | B2 |
9770577 | Li et al. | Sep 2017 | B2 |
9775621 | Tompkins et al. | Oct 2017 | B2 |
9775706 | Peterson et al. | Oct 2017 | B2 |
9775732 | Khenansho | Oct 2017 | B2 |
9788800 | Mayoras, Jr. | Oct 2017 | B2 |
9795391 | Saatchi et al. | Oct 2017 | B2 |
9801980 | Karino et al. | Oct 2017 | B2 |
9808599 | Bowman et al. | Nov 2017 | B2 |
9833252 | Sepetka et al. | Dec 2017 | B2 |
9833604 | Lam et al. | Dec 2017 | B2 |
9833625 | Waldhauser et al. | Dec 2017 | B2 |
10028759 | Wallace et al. | Jul 2018 | B2 |
10149692 | Turjman et al. | Dec 2018 | B2 |
10265086 | Vale | Apr 2019 | B2 |
10716915 | Ogle et al. | Jul 2020 | B2 |
10610668 | Burkholz et al. | Aug 2020 | B2 |
20010001315 | Bates | May 2001 | A1 |
20010016755 | Addis | Aug 2001 | A1 |
20010041899 | Foster | Nov 2001 | A1 |
20010044598 | Parodi | Nov 2001 | A1 |
20010051810 | Dubrul | Dec 2001 | A1 |
20020002383 | Sepetka et al. | Jan 2002 | A1 |
20020016609 | Wensel | Feb 2002 | A1 |
20020022859 | Hogendijk | Feb 2002 | A1 |
20020026211 | Khosravi | Feb 2002 | A1 |
20020049468 | Streeter | Apr 2002 | A1 |
20020052620 | Barvut | May 2002 | A1 |
20020068954 | Foster | Jun 2002 | A1 |
20020072764 | Sepetka | Jun 2002 | A1 |
20020082558 | Samson | Jun 2002 | A1 |
20020091407 | Zadno-Azizi et al. | Jul 2002 | A1 |
20020095171 | Belef | Jul 2002 | A1 |
20020123765 | Sepetka | Sep 2002 | A1 |
20020143362 | Macoviak et al. | Oct 2002 | A1 |
20020156455 | Barbut | Oct 2002 | A1 |
20020161393 | Demond | Oct 2002 | A1 |
20020165576 | Boyle et al. | Nov 2002 | A1 |
20020173819 | Leeflang et al. | Nov 2002 | A1 |
20020177800 | Bagaoisan et al. | Nov 2002 | A1 |
20020188276 | Evans | Dec 2002 | A1 |
20030004536 | Boylan et al. | Jan 2003 | A1 |
20030004538 | Secrest | Jan 2003 | A1 |
20030004542 | Wensel | Jan 2003 | A1 |
20030009146 | Muni | Jan 2003 | A1 |
20030009191 | Wensel | Jan 2003 | A1 |
20030023204 | Vo et al. | Jan 2003 | A1 |
20030040769 | Kelley et al. | Feb 2003 | A1 |
20030040772 | Hyodoh et al. | Feb 2003 | A1 |
20030050663 | Khachin | Mar 2003 | A1 |
20030105484 | Boyle et al. | Jun 2003 | A1 |
20030125798 | Matrin | Jul 2003 | A1 |
20030130682 | Broome et al. | Jul 2003 | A1 |
20030144687 | Brady et al. | Jul 2003 | A1 |
20030153940 | Nohilly et al. | Aug 2003 | A1 |
20030153943 | Michael et al. | Aug 2003 | A1 |
20030153944 | Phung | Aug 2003 | A1 |
20030163064 | Vrba | Aug 2003 | A1 |
20030163158 | Wlite | Aug 2003 | A1 |
20030171769 | Barbut | Sep 2003 | A1 |
20030176884 | Berrada et al. | Sep 2003 | A1 |
20030195537 | Dubrul | Oct 2003 | A1 |
20030195554 | Shen | Oct 2003 | A1 |
20030199917 | Knudson | Oct 2003 | A1 |
20030204202 | Palmer | Oct 2003 | A1 |
20030212430 | Bose | Nov 2003 | A1 |
20030216611 | Vu | Nov 2003 | A1 |
20030236533 | Wilson | Dec 2003 | A1 |
20040010280 | Adams et al. | Jan 2004 | A1 |
20040010282 | Kusleika | Jan 2004 | A1 |
20040014002 | Lundgren | Jan 2004 | A1 |
20040068288 | Palmer et al. | Apr 2004 | A1 |
20040073243 | Sepetka | Apr 2004 | A1 |
20040079429 | Miller | Apr 2004 | A1 |
20040082962 | Demarais | Apr 2004 | A1 |
20040093065 | Yachia et al. | May 2004 | A1 |
20040133231 | Maitland | Jul 2004 | A1 |
20040138692 | Phung | Jul 2004 | A1 |
20040153118 | Clubb | Aug 2004 | A1 |
20040193107 | Pierpont et al. | Sep 2004 | A1 |
20040199202 | Dubrul et al. | Oct 2004 | A1 |
20040260333 | Dubrul et al. | Dec 2004 | A1 |
20050015047 | Shah | Jan 2005 | A1 |
20050020974 | Noriega | Jan 2005 | A1 |
20050033348 | Sepetka | Feb 2005 | A1 |
20050038447 | Huffmaster | Feb 2005 | A1 |
20050038468 | Panetta et al. | Feb 2005 | A1 |
20050049619 | Sepetka | Mar 2005 | A1 |
20050049669 | Jones | Mar 2005 | A1 |
20050049670 | Jones et al. | Mar 2005 | A1 |
20050055033 | Leslie et al. | Mar 2005 | A1 |
20050055047 | Greenhalgh | Mar 2005 | A1 |
20050059995 | Sepetka | Mar 2005 | A1 |
20050085849 | Sepetka | Apr 2005 | A1 |
20050090857 | Kusleika et al. | Apr 2005 | A1 |
20050125024 | Sepetka | Jun 2005 | A1 |
20050171566 | Kanamaru | Aug 2005 | A1 |
20050187570 | Nguyen et al. | Aug 2005 | A1 |
20050267491 | Kellett et al. | Aug 2005 | A1 |
20050216030 | Sepetka | Sep 2005 | A1 |
20050216050 | Sepetka | Sep 2005 | A1 |
20050288686 | Sepetka | Sep 2005 | A1 |
20050228417 | Teitelbaum et al. | Oct 2005 | A1 |
20060009785 | Maitland | Jan 2006 | A1 |
20060009799 | Kleshinski et al. | Jan 2006 | A1 |
20060010636 | Vacher | Jan 2006 | A1 |
20060030933 | DeLeggge et al. | Feb 2006 | A1 |
20060058836 | Bose | Mar 2006 | A1 |
20060058837 | Bose | Mar 2006 | A1 |
20060058838 | Bose | Mar 2006 | A1 |
20060064151 | Guterman | Mar 2006 | A1 |
20060149313 | Arguello et al. | Jul 2006 | A1 |
20060155305 | Freudenthal | Jul 2006 | A1 |
20060155322 | Sater et al. | Jul 2006 | A1 |
20060161187 | Levine et al. | Jul 2006 | A1 |
20060195137 | Sepetka | Aug 2006 | A1 |
20060224177 | Finitsis | Oct 2006 | A1 |
20060224179 | Kucharczyk | Oct 2006 | A1 |
20060229638 | Abrams et al. | Oct 2006 | A1 |
20060282111 | Morsi | Dec 2006 | A1 |
20060287701 | Pal | Dec 2006 | A1 |
20070088383 | Pal et al. | Apr 2007 | A1 |
20070142858 | Bates | Jun 2007 | A1 |
20070149996 | Coughlin | Jun 2007 | A1 |
20070156170 | Hancock | Jul 2007 | A1 |
20070165170 | Fukuda | Jul 2007 | A1 |
20070191866 | Palmer et al. | Aug 2007 | A1 |
20070198028 | Miloslavski | Aug 2007 | A1 |
20070198051 | Clubb et al. | Aug 2007 | A1 |
20070198075 | Levy | Aug 2007 | A1 |
20070208367 | Fiorella | Sep 2007 | A1 |
20070208371 | French | Sep 2007 | A1 |
20070213765 | Adams et al. | Sep 2007 | A1 |
20070225749 | Martin | Sep 2007 | A1 |
20070239254 | Chia et al. | Oct 2007 | A1 |
20070244505 | Gilson et al. | Oct 2007 | A1 |
20070270902 | Slazas et al. | Nov 2007 | A1 |
20070288038 | Bimbo | Dec 2007 | A1 |
20080045881 | Teitelbaum et al. | Feb 2008 | A1 |
20080082107 | Miller et al. | Apr 2008 | A1 |
20080086190 | Ta | Apr 2008 | A1 |
20080091223 | Pokorney | Apr 2008 | A1 |
20080097398 | Mitelberg | Apr 2008 | A1 |
20080109031 | Sepetka | May 2008 | A1 |
20080109032 | Sepetka | May 2008 | A1 |
20080119886 | Greenhalgh et al. | May 2008 | A1 |
20080177296 | Sepetka | Jul 2008 | A1 |
20080183197 | Sepetka | Jul 2008 | A1 |
20080183198 | Sepetka | Jul 2008 | A1 |
20080183205 | Sepetka | Jul 2008 | A1 |
20080188876 | Sepetka | Aug 2008 | A1 |
20080188885 | Sepetka | Aug 2008 | A1 |
20080188928 | Salahieh | Aug 2008 | A1 |
20080200946 | Braun | Aug 2008 | A1 |
20080215077 | Sepetka | Sep 2008 | A1 |
20080221600 | Dieck et al. | Sep 2008 | A1 |
20080228209 | DeMello et al. | Sep 2008 | A1 |
20080234706 | Sepetka | Sep 2008 | A1 |
20080243170 | Jenson | Oct 2008 | A1 |
20080255596 | Jenson | Oct 2008 | A1 |
20080262528 | Martin | Oct 2008 | A1 |
20080262532 | Martin | Oct 2008 | A1 |
20080275488 | Fleming | Nov 2008 | A1 |
20080275493 | Farmiga | Nov 2008 | A1 |
20080281350 | Sepetka | Nov 2008 | A1 |
20080312681 | Ansel | Dec 2008 | A1 |
20090024157 | Anukhin | Jan 2009 | A1 |
20090054918 | Henson | Feb 2009 | A1 |
20090069828 | Martin | Mar 2009 | A1 |
20090076539 | Valaie | Mar 2009 | A1 |
20090105722 | Fulkerson | Apr 2009 | A1 |
20090105737 | Fulkerson | Apr 2009 | A1 |
20090131908 | McKay | May 2009 | A1 |
20090163846 | Aklog et al. | May 2009 | A1 |
20090177206 | Lozier et al. | Jul 2009 | A1 |
20090182336 | Brenzel et al. | Jul 2009 | A1 |
20090221967 | Thommen et al. | Sep 2009 | A1 |
20090270815 | Stamp et al. | Oct 2009 | A1 |
20090281610 | Parker | Nov 2009 | A1 |
20090292297 | Ferrere | Nov 2009 | A1 |
20090292307 | Razack | Nov 2009 | A1 |
20090299374 | Tilson et al. | Dec 2009 | A1 |
20090299393 | Martin | Dec 2009 | A1 |
20090306702 | Miloslavski | Dec 2009 | A1 |
20100004607 | Wilson et al. | Jan 2010 | A1 |
20100030186 | Stivland | Feb 2010 | A1 |
20100030256 | Dubrul et al. | Feb 2010 | A1 |
20100087908 | Hilaire | Apr 2010 | A1 |
20100114017 | Lenker | May 2010 | A1 |
20100125326 | Kalstad | May 2010 | A1 |
20100125327 | Agnew | May 2010 | A1 |
20100191272 | Keating | Jul 2010 | A1 |
20100211094 | Sargent, Jr. | Aug 2010 | A1 |
20100249815 | Jantzen et al. | Sep 2010 | A1 |
20100268264 | Bonnett et al. | Oct 2010 | A1 |
20100268265 | Krolik et al. | Oct 2010 | A1 |
20100292726 | Olsen et al. | Nov 2010 | A1 |
20100305604 | Pah | Dec 2010 | A1 |
20100318178 | Rapaport et al. | Dec 2010 | A1 |
20100324649 | Mattsson | Dec 2010 | A1 |
20100331949 | Habib | Dec 2010 | A1 |
20110009875 | Grandfield et al. | Jan 2011 | A1 |
20110009940 | Grandfield et al. | Jan 2011 | A1 |
20110009942 | Gregorich | Jan 2011 | A1 |
20110022149 | Cox et al. | Jan 2011 | A1 |
20110054514 | Arcand | Mar 2011 | A1 |
20110054516 | Keegan | Mar 2011 | A1 |
20110060359 | Hannes | Mar 2011 | A1 |
20110077620 | deBeer | Mar 2011 | A1 |
20110098683 | Wiita et al. | Apr 2011 | A1 |
20110054504 | Wolf et al. | May 2011 | A1 |
20110125181 | Brady et al. | May 2011 | A1 |
20110130756 | Everson, Jr | Jun 2011 | A1 |
20110152920 | Eckhouse et al. | Jun 2011 | A1 |
20110160763 | Ferrera et al. | Jun 2011 | A1 |
20110166586 | Sepetka et al. | Jul 2011 | A1 |
20110196414 | Porter et al. | Aug 2011 | A1 |
20110202088 | Eckhouse et al. | Aug 2011 | A1 |
20110213290 | Chin et al. | Sep 2011 | A1 |
20110213297 | Aklog et al. | Sep 2011 | A1 |
20110213393 | Aklog et al. | Sep 2011 | A1 |
20110213403 | Aboytes | Sep 2011 | A1 |
20110218564 | Drasler et al. | Sep 2011 | A1 |
20110224707 | Miloslavaski et al. | Sep 2011 | A1 |
20110264132 | Strauss et al. | Oct 2011 | A1 |
20110276120 | Gilson et al. | Nov 2011 | A1 |
20110319917 | Ferrera et al. | Dec 2011 | A1 |
20120041449 | Eckhouse et al. | Feb 2012 | A1 |
20120041474 | Eckhouse et al. | Feb 2012 | A1 |
20120059356 | diPama et al. | Mar 2012 | A1 |
20120089216 | Rapaport et al. | Apr 2012 | A1 |
20120101510 | Lenker et al. | Apr 2012 | A1 |
20120116351 | Chomas et al. | May 2012 | A1 |
20120116440 | Leynov et al. | May 2012 | A1 |
20120143237 | Cam et al. | Jun 2012 | A1 |
20120143239 | Aklog et al. | Jun 2012 | A1 |
20120150147 | Leynov et al. | Jun 2012 | A1 |
20120165858 | Eckhouse et al. | Jun 2012 | A1 |
20120165859 | Eckhouse et al. | Jun 2012 | A1 |
20120215250 | Grandfield et al. | Aug 2012 | A1 |
20120277788 | Cattaneo | Nov 2012 | A1 |
20120283768 | Cox et al. | Nov 2012 | A1 |
20120296362 | Cam et al. | Nov 2012 | A1 |
20120316600 | Ferrera et al. | Dec 2012 | A1 |
20130030461 | Marks et al. | Jan 2013 | A1 |
20130046330 | McIntosh et al. | Feb 2013 | A1 |
20130046333 | Jones et al. | Feb 2013 | A1 |
20130046334 | Jones et al. | Feb 2013 | A1 |
20130116774 | Strauss et al. | May 2013 | A1 |
20130131614 | Hassan et al. | May 2013 | A1 |
20130144326 | Brady et al. | Jun 2013 | A1 |
20130144328 | Weber et al. | Jun 2013 | A1 |
20130158592 | Porter | Jun 2013 | A1 |
20130184703 | Shireman et al. | Jul 2013 | A1 |
20130184739 | Brady et al. | Jul 2013 | A1 |
20130197567 | Brady et al. | Aug 2013 | A1 |
20130226146 | Tekulve | Aug 2013 | A1 |
20130268050 | Wilson et al. | Oct 2013 | A1 |
20130281788 | Garrison | Oct 2013 | A1 |
20130325055 | Eckhouse et al. | Dec 2013 | A1 |
20130325056 | Eckhouse et al. | Dec 2013 | A1 |
20130345739 | Brady et al. | Dec 2013 | A1 |
20140046359 | Bowman et al. | Feb 2014 | A1 |
20140121672 | Folk | May 2014 | A1 |
20140128905 | Molaei | May 2014 | A1 |
20140135812 | Divino et al. | May 2014 | A1 |
20140180377 | Bose et al. | Jun 2014 | A1 |
20140188127 | Dubrul et al. | Jul 2014 | A1 |
20140194919 | Losardo et al. | Jul 2014 | A1 |
20140200607 | Sepetka et al. | Jul 2014 | A1 |
20140200608 | Brady et al. | Jul 2014 | A1 |
20140236220 | Inoue | Aug 2014 | A1 |
20140257362 | Eldenschink | Sep 2014 | A1 |
20140276922 | McLain et al. | Sep 2014 | A1 |
20140277053 | Wang et al. | Sep 2014 | A1 |
20140277079 | Vale et al. | Sep 2014 | A1 |
20140309657 | Ben-Ami | Oct 2014 | A1 |
20140309673 | Dacuycuy et al. | Oct 2014 | A1 |
20140330302 | Tekulve et al. | Nov 2014 | A1 |
20140343585 | Ferrera et al. | Nov 2014 | A1 |
20140364896 | Consigny | Dec 2014 | A1 |
20140371769 | Vale et al. | Dec 2014 | A1 |
20140371779 | Vale et al. | Dec 2014 | A1 |
20140371780 | Vale et al. | Dec 2014 | A1 |
20140379023 | Brady et al. | Dec 2014 | A1 |
20150018859 | Quick et al. | Jan 2015 | A1 |
20150018860 | Quick et al. | Jan 2015 | A1 |
20150080937 | Davidson | Mar 2015 | A1 |
20150081003 | Wainwright et al. | Mar 2015 | A1 |
20150112376 | Molaei et al. | Apr 2015 | A1 |
20150133990 | Davidson | May 2015 | A1 |
20150142043 | Furey | May 2015 | A1 |
20150164523 | Brady et al. | Jun 2015 | A1 |
20150238314 | Bortlein | Aug 2015 | A1 |
20150250497 | Marks et al. | Sep 2015 | A1 |
20150257775 | Gilvarry et al. | Sep 2015 | A1 |
20150297252 | Miloslavski et al. | Oct 2015 | A1 |
20150313617 | Grandfield et al. | Nov 2015 | A1 |
20150320431 | Ulm, III | Nov 2015 | A1 |
20150351770 | Fulton, III | Dec 2015 | A1 |
20150352325 | Quick | Dec 2015 | A1 |
20150359547 | Vale et al. | Dec 2015 | A1 |
20150374391 | Quick et al. | Dec 2015 | A1 |
20150374393 | Brady et al. | Dec 2015 | A1 |
20150374479 | Vale | Dec 2015 | A1 |
20160015402 | Brady et al. | Jan 2016 | A1 |
20160022296 | Brady et al. | Jan 2016 | A1 |
20160066921 | Brady et al. | Mar 2016 | A1 |
20160106448 | Brady et al. | Apr 2016 | A1 |
20160106449 | Brady et al. | Apr 2016 | A1 |
20160113663 | Brady et al. | Apr 2016 | A1 |
20160113664 | Brady et al. | Apr 2016 | A1 |
20160113665 | Brady et al. | Apr 2016 | A1 |
20160120558 | Brady et al. | May 2016 | A1 |
20160121080 | Cottone | May 2016 | A1 |
20160135829 | Holochwost | May 2016 | A1 |
20160143653 | Vale et al. | May 2016 | A1 |
20160151079 | Aklog et al. | Jun 2016 | A1 |
20160192953 | Brady et al. | Jul 2016 | A1 |
20160192954 | Brady et al. | Jul 2016 | A1 |
20160192955 | Brady et al. | Jul 2016 | A1 |
20160192956 | Brady et al. | Jul 2016 | A1 |
20160228134 | Martin et al. | Aug 2016 | A1 |
20160256180 | Vale et al. | Sep 2016 | A1 |
20160262880 | Li et al. | Sep 2016 | A1 |
20160317168 | Brady et al. | Nov 2016 | A1 |
20170007264 | Cruise et al. | Jan 2017 | A1 |
20170007265 | Guo et al. | Jan 2017 | A1 |
20170020670 | Murray et al. | Jan 2017 | A1 |
20170020700 | Bienvenu et al. | Jan 2017 | A1 |
20170027640 | Kunis et al. | Feb 2017 | A1 |
20170027692 | Bonhoeffer | Feb 2017 | A1 |
20170027725 | Argentine | Feb 2017 | A1 |
20170035436 | Morita | Feb 2017 | A1 |
20170035567 | Duffy | Feb 2017 | A1 |
20170042548 | Lam | Feb 2017 | A1 |
20170049596 | Schabert | Feb 2017 | A1 |
20170065401 | Fearnot et al. | Mar 2017 | A1 |
20170071614 | Vale et al. | Mar 2017 | A1 |
20170071737 | Kelley | Mar 2017 | A1 |
20170072452 | Monetti et al. | Mar 2017 | A1 |
20170079671 | Morero et al. | Mar 2017 | A1 |
20170079680 | Bowman | Mar 2017 | A1 |
20170079766 | Wang et al. | Mar 2017 | A1 |
20170079767 | Leon-Yip | Mar 2017 | A1 |
20170079812 | Lam et al. | Mar 2017 | A1 |
20170079817 | Sepetka et al. | Mar 2017 | A1 |
20170079819 | Pung et al. | Mar 2017 | A1 |
20170079820 | Lam et al. | Mar 2017 | A1 |
20170086851 | Wallace et al. | Mar 2017 | A1 |
20170086862 | Vale et al. | Mar 2017 | A1 |
20170086863 | Brady et al. | Mar 2017 | A1 |
20170086996 | Peterson et al. | Mar 2017 | A1 |
20170095259 | Tompkins et al. | Apr 2017 | A1 |
20170100126 | Bowman et al. | Apr 2017 | A1 |
20170100141 | Morero et al. | Apr 2017 | A1 |
20170100143 | Granfield | Apr 2017 | A1 |
20170100183 | Iaizzo et al. | Apr 2017 | A1 |
20170105743 | Vale et al. | Apr 2017 | A1 |
20170112515 | Brady et al. | Apr 2017 | A1 |
20170113023 | Steingisser et al. | Apr 2017 | A1 |
20170147765 | Mehta | May 2017 | A1 |
20170151032 | Loisel | Jun 2017 | A1 |
20170165062 | Rothstein | Jun 2017 | A1 |
20170165065 | Rothstein et al. | Jun 2017 | A1 |
20170165454 | Tuohy et al. | Jun 2017 | A1 |
20170172554 | Bortlein et al. | Jun 2017 | A1 |
20170172581 | Bose et al. | Jun 2017 | A1 |
20170172766 | Vong et al. | Jun 2017 | A1 |
20170172772 | Khenansho | Jun 2017 | A1 |
20170189033 | Sepetka et al. | Jul 2017 | A1 |
20170189035 | Porter | Jul 2017 | A1 |
20170215902 | Leynov et al. | Aug 2017 | A1 |
20170216484 | Cruise et al. | Aug 2017 | A1 |
20170224350 | Shimizu et al. | Aug 2017 | A1 |
20170224355 | Bowman et al. | Aug 2017 | A1 |
20170224467 | Piccagli et al. | Aug 2017 | A1 |
20170224511 | Dwork et al. | Aug 2017 | A1 |
20170224953 | Tran et al. | Aug 2017 | A1 |
20170231749 | Perkins et al. | Aug 2017 | A1 |
20170252064 | Staunton | Sep 2017 | A1 |
20170265983 | Lam et al. | Sep 2017 | A1 |
20170281192 | Tieu et al. | Oct 2017 | A1 |
20170281331 | Perkins et al. | Oct 2017 | A1 |
20170281344 | Costello | Oct 2017 | A1 |
20170281909 | Northrop et al. | Oct 2017 | A1 |
20170281912 | Melder et al. | Oct 2017 | A1 |
20170290593 | Cruise et al. | Oct 2017 | A1 |
20170290654 | Sethna | Oct 2017 | A1 |
20170296324 | Argentine | Oct 2017 | A1 |
20170296325 | Marrocco et al. | Oct 2017 | A1 |
20170303939 | Greenhalgh et al. | Oct 2017 | A1 |
20170303942 | Greenhalgh et al. | Oct 2017 | A1 |
20170303947 | Greenhalgh et al. | Oct 2017 | A1 |
20170303948 | Wallace et al. | Oct 2017 | A1 |
20170304041 | Argentine | Oct 2017 | A1 |
20170304097 | Corwin et al. | Oct 2017 | A1 |
20170304595 | Nagasrinivasa et al. | Oct 2017 | A1 |
20170312109 | Le | Nov 2017 | A1 |
20170312484 | Shipley et al. | Nov 2017 | A1 |
20170316561 | Helm et al. | Nov 2017 | A1 |
20170319826 | Bowman et al. | Nov 2017 | A1 |
20170333228 | Orth et al. | Nov 2017 | A1 |
20170333236 | Greenan | Nov 2017 | A1 |
20170333678 | Bowman et al. | Nov 2017 | A1 |
20170340383 | Bloom et al. | Nov 2017 | A1 |
20170348014 | Wallace et al. | Dec 2017 | A1 |
20170348514 | Guyon et al. | Dec 2017 | A1 |
20180042623 | Batiste | Feb 2018 | A1 |
20180193591 | Jaroch et al. | Jul 2018 | A1 |
20180235743 | Farago et al. | Aug 2018 | A1 |
20190021759 | Krolik et al. | Jan 2019 | A1 |
20190046219 | Marchand et al. | Feb 2019 | A1 |
20190192175 | Chida et al. | Jun 2019 | A1 |
20190209206 | Patel et al. | Jul 2019 | A1 |
20190216476 | Barry et al. | Jul 2019 | A1 |
20190255290 | Snyder et al. | Aug 2019 | A1 |
20190365411 | Avneri et al. | Dec 2019 | A1 |
Number | Date | Country |
---|---|---|
1972728 | May 2007 | CN |
103071195 | May 2013 | CN |
104507380 | Apr 2015 | CN |
104905873 | Sep 2015 | CN |
105307582 | Feb 2016 | CN |
105726163 | Jul 2016 | CN |
106232059 | Dec 2016 | CN |
20 2009 001 951 | Apr 2010 | DE |
10 2009 056 450 | Jun 2011 | DE |
10 2010 010 849 | Sep 2011 | DE |
10 2010 014 778 | Oct 2011 | DE |
10 2010 024 085 | Dec 2011 | DE |
10 2011 014 586 | Sep 2012 | DE |
2301450 | Mar 2011 | EP |
2628455 | Aug 2013 | EP |
3302312 | Apr 2018 | EP |
2498349 | Jul 2013 | GB |
9-19438 | Jan 1997 | JP |
WO 9304722 | Mar 1993 | WO |
9424926 | Nov 1994 | WO |
9727808 | Aug 1997 | WO |
9738631 | Oct 1997 | WO |
9920335 | Apr 1999 | WO |
9956801 | Nov 1999 | WO |
9960933 | Dec 1999 | WO |
0121077 | Mar 2001 | WO |
0202162 | Jan 2002 | WO |
0211627 | Feb 2002 | WO |
0243616 | Jun 2002 | WO |
02070061 | Sep 2002 | WO |
02094111 | Nov 2002 | WO |
03002006 | Jan 2003 | WO |
03018085 | Mar 2003 | WO |
03030751 | Apr 2003 | WO |
03051448 | Jun 2003 | WO |
2004028571 | Apr 2004 | WO |
2004056275 | Jul 2004 | WO |
2005000130 | Jan 2005 | WO |
2005027751 | Mar 2005 | WO |
2005027779 | Mar 2005 | WO |
2006021407 | Mar 2006 | WO |
2006031410 | Mar 2006 | WO |
2006107641 | Oct 2006 | WO |
2006135823 | Dec 2006 | WO |
2007054307 | May 2007 | WO |
2007068424 | Jun 2007 | WO |
2008034615 | Mar 2008 | WO |
2008051431 | May 2008 | WO |
2008131116 | Oct 2008 | WO |
2009019664 | Feb 2009 | WO |
2009031338 | Mar 2009 | WO |
2009076482 | Jun 2009 | WO |
2009086482 | Jul 2009 | WO |
2009105710 | Aug 2009 | WO |
WO 2009103125 | Aug 2009 | WO |
2010010545 | Jan 2010 | WO |
2010046897 | Apr 2010 | WO |
2010075565 | Jul 2010 | WO |
2010102307 | Sep 2010 | WO |
2010146581 | Dec 2010 | WO |
2011013556 | Feb 2011 | WO |
2011066961 | Jun 2011 | WO |
2011082319 | Jul 2011 | WO |
2011095352 | Aug 2011 | WO |
2011106426 | Sep 2011 | WO |
2011110316 | Sep 2011 | WO |
2012052982 | Apr 2012 | WO |
2012064726 | May 2012 | WO |
2012081020 | Jun 2012 | WO |
2012110619 | Aug 2012 | WO |
2012120490 | Sep 2012 | WO |
2012156924 | Nov 2012 | WO |
2013016435 | Jan 2013 | WO |
2013072777 | May 2013 | WO |
2013105099 | Jul 2013 | WO |
2013109756 | Jul 2013 | WO |
2014081892 | May 2014 | WO |
2014139845 | Sep 2014 | WO |
2014169266 | Oct 2014 | WO |
2014178198 | Nov 2014 | WO |
2015061365 | Apr 2015 | WO |
2015134625 | Sep 2015 | WO |
2015179324 | Nov 2015 | WO |
WO 2015179377 | Nov 2015 | WO |
2015189354 | Dec 2015 | WO |
2016010995 | Jan 2016 | WO |
WO 2017004234 | Jan 2017 | WO |
2018193603 | Oct 2018 | WO |
WO 2018178979 | Oct 2018 | WO |
WO 2019064306 | Apr 2019 | WO |
WO 2019079296 | Apr 2019 | WO |
WO 2020139979 | Jul 2020 | WO |
Entry |
---|
US 6,348,062 B1, 02/2002, Hopkins (withdrawn) |
Extended European Search Report dated Jul. 28, 2021 issued in European Patent Application No. 20 21 0069. |
Extended European Search Report dated Aug. 5, 2021 issued in European Patent Application No. 21 16 7037. |
Number | Date | Country | |
---|---|---|---|
20200281611 A1 | Sep 2020 | US |
Number | Date | Country | |
---|---|---|---|
62813723 | Mar 2019 | US |